Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 19, 2023

Outcomes of Patients With TP53-Mutated AML Receiving Allogeneic HSCT After First Induction or Salvage Therapy



Additional Info

Disclosure statements are available on the authors' profiles:

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Leukemia 2023 Feb 18;[EPub Ahead of Print], T Badar, E Atallah, R Shallis, AN Saliba, A Patel, JP Bewersdorf, J Grenet, M Stahl, A Duvall, M Burkart, N Palmisiano, D Bradshaw, M Kubiak, S Dinner, AD Goldberg, Y Abaza, GSG Murthy, V Kota, MR Litzow

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading